OncoMatch/Clinical Trials/NCT05637216
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
Is NCT05637216 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Losartan 25 milligram capsule for radiation induced fibrosis.
Treatment: Losartan 25 milligram capsule — This study will evaluate the efficacy of losartan (LOS), an FDA-approved transforming growth factor beta-1 (TGF-β1) blocker, to decrease radiation induced fibrosis (RIF) in the breast and the lung of breast cancer patients, testing the hypothesis that Losartan will decrease RIF, TGF- β1 and cellular senescence/inflammation in the breast and the lung of irradiated breast cancer patients relative to placebo treatment and consequently improve clinical outcomes in breast cancer patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Excluded: ATM mutation
Excluded: RAD21 mutation
Excluded: TGFB1 c-509t single-nucleotide polymorphism
Disease stage
Required: Stage 0, I, II, III, IV, TIS, TX
clinical or pathologic stage 0-IV invasive breast cancer to include ductal carcinoma in situ (Tis), primary tumor cannot be assessed (TX) and all other primary tumor stage categories (T1-T4)
Demographics
Prior therapy
Must have received: surgery
Has been treated with breast conserving surgery or mastectomy with reconstruction
Cannot have received: radiation therapy
Exception: prior breast radiation therapy
history of prior breast radiation therapy
Lab requirements
Kidney function
creatine ≤ 1.5 x uln, egfr ≥ 60
Liver function
ast ≤ 2.5 x uln, alt ≤ 2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Vail Health Shaw Cancer Center · Edwards, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05637216 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Are patients with ATM alterations eligible?
No. ATM mutation is an exclusion criterion.
Are patients with RAD21 alterations eligible?
No. RAD21 mutation is an exclusion criterion.
What disease stage is eligible?
Stage 0 or I or II or III or IV or TIS or TX is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify